221384A6-059C-4731-9BD0-68EC9CA5651D
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 2.0367936925098555
- age_years
- 37
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- NOTCH_SIGNALING+0.398
- HEDGEHOG_SIGNALING+0.381
- TGF_BETA_SIGNALING+0.365
- WNT_BETA_CATENIN_SIGNALING+0.322
- MITOTIC_SPINDLE+0.263
- MYC_TARGETS_V2+0.236
- UNFOLDED_PROTEIN_RESPONSE+0.225
- DNA_REPAIR+0.220
- INTERFERON_ALPHA_RESPONSE+0.208
- CHOLESTEROL_HOMEOSTASIS+0.202
Top 10 suppressed
- KRAS_SIGNALING_DN-0.335
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.308
- SPERMATOGENESIS-0.283
- ALLOGRAFT_REJECTION-0.260
- COAGULATION-0.247
- INFLAMMATORY_RESPONSE-0.238
- MYOGENESIS-0.232
- TNFA_SIGNALING_VIA_NFKB-0.199
- ANGIOGENESIS-0.196
- COMPLEMENT-0.175
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | A1203AFB-95EC-4EAF-9290-BDB74432403C | — | — | 0.887 |
| 2 | E6090BC6-D29D-4401-990A-251930CC6853 | — | — | 0.864 |
| 3 | SRR934799 | — | — | 0.861 |
| 4 | 2CB84056-3B7C-4E12-9403-596B76CCF96B | — | — | 0.854 |
| 5 | 4992152D-1D3D-4156-9D80-1B6810AAE78F | — | — | 0.854 |
| 6 | A770E81F-8898-4632-A839-7950EED7CF7A | — | — | 0.852 |
| 7 | EFEDAFE3-FF81-47ED-97F6-1193EA375D77 | — | — | 0.844 |
| 8 | SRR934838 | — | — | 0.843 |
| 9 | DB57CFA5-B8EA-4A08-B6CC-EF55C0E213D4 | — | — | 0.834 |
| 10 | DEB3BE77-120D-4EC5-AA7A-4B2952F2C832 | — | — | 0.830 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 27 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| NOTCH_SIGNALING | 0.398 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.381 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.365 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.322 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.263 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.236 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.225 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.220 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.208 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.202 | Remibrutinib | — uncovered |
| PROTEIN_SECRETION | 0.197 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.164 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.151 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.147 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.136 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.106 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.103 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.064 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.064 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.060 | Inavolisib | — uncovered |